Zhang Wenxin, Dong Weichen, Cheng Chen, Zhao Hongting, Liu Yutong, Zaydel Kristina, Frech Liora, Xing Zhiyao, Zhu Wusheng, Zhou Bing, Li Yi, Meyron-Holtz Esther G, Li Kuanyu
State Key Laboratory of Pharmaceutical Biotechnology, Department of Vascular Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, China.
State Key Laboratory of Pharmaceutical Biotechnology, Department of Neurology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
J Extracell Vesicles. 2025 Jun;14(6):e70105. doi: 10.1002/jev2.70105.
The incidence of inflammatory bowel disease (IBD) is on the rise, yet current clinical treatments are limited. Previous studies have identified impairments in both systemic and local iron metabolism in IBD patients. However, the impact of iron dyshomeostasis on the development and pathogenesis of IBD remains elusive. In this study, we confirmed iron deposition in inflamed intestinal lesions of IBD patients and mice with DSS-induced colitis, accompanied by distinct distribution patterns of the iron storage protein ferritin. To reveal the role of ferritin in the involvement of pathology of IBD, we constructed intestinal epithelial cell- or myeloid-specific ferritin H (FtH) knockout mice and demonstrated that intestinal epithelial cells (IECs) release extracellular vesicles (EVs) that contain iron-loaded ferritin. These EVs are internalized by macrophages via the macrophage scavenger receptor 1 (Msr1), leading to the activation of inflammatory responses and oxidative stress, thereby exacerbating colitis severity. Genetic deletion of FtH in IECs or blockage of macrophage ferritin uptake, either through Msr1 inhibitor fucoidan or through Msr1 knockdown (KD), suppressed inflammatory symptoms. Thus, EVs containing iron-loaded ferritin released from IECs activate macrophages and contribute to IBD development, supporting that IBD patients with iron deficiency anaemia are often prescribed iron supplementation in a remission phase, other than in an active phase of the disease. Pharmacological inhibition of this ferritin secretion and engulfing process provides a therapeutic target for the disease.
炎症性肠病(IBD)的发病率正在上升,但目前的临床治疗方法有限。先前的研究已经确定IBD患者存在全身和局部铁代谢障碍。然而,铁稳态失衡对IBD发生发展和发病机制的影响仍不清楚。在本研究中,我们证实了IBD患者和DSS诱导的结肠炎小鼠的炎症性肠道病变中存在铁沉积,同时铁储存蛋白铁蛋白具有不同的分布模式。为了揭示铁蛋白在IBD病理过程中的作用,我们构建了肠道上皮细胞或髓系特异性铁蛋白H(FtH)基因敲除小鼠,并证明肠道上皮细胞(IECs)释放含有铁负载铁蛋白的细胞外囊泡(EVs)。这些EVs通过巨噬细胞清道夫受体1(Msr1)被巨噬细胞内化,导致炎症反应和氧化应激激活,从而加剧结肠炎的严重程度。通过Msr1抑制剂岩藻依聚糖或Msr1基因敲低(KD),在IECs中基因删除FtH或阻断巨噬细胞铁蛋白摄取,均可抑制炎症症状。因此,IECs释放的含有铁负载铁蛋白的EVs激活巨噬细胞并促进IBD的发展,这支持了IBD合并缺铁性贫血的患者通常在缓解期而非疾病活动期进行铁补充治疗。对这种铁蛋白分泌和吞噬过程的药理学抑制为该疾病提供了一个治疗靶点。